Applied Clinical Trials Magazine

??Our October issue is LIVE?? New Trends and Tactics in Outsourcing??Achieving Optimal Adoption of RBQM??The Evolution of Real-World Evidence??and so much more right here?? https://lnkd.in/ecebCNQt

Former Chief Oncology Officer and Executive Vice President, Chris Boshoff, MD, PhD, FMedSci will assume the role and lead all R&D functions including #oncology

?? Mark Melton, vice president of biospecimen data and operations, Slope talks challenges at the site-level with collection.

Novel Support for Sites: Ensuring Clinical Trial Delivery and Sponsor Confidence Discover how IQVIA is transforming clinical trials with patient- and site-centric solutions. Join industry experts Dana Poff and Alison Liddy in our live webinar tomorrow to explore strategies that enhance recruitment, mitigate risks, and reduce site burden, driving successful trial outcomes. Don’t miss this opportunity to see innovation in action. Register now: https://lnkd.in/e7HrwCNW

?? Excited to share a game-changing publication in Applied Clinical Trials Magazine ! ?? Mats Sundgren, Rohit Mistry and Gabriel Maeztu have collaborated to write the article "Harnessing Unstructured Data and Hospital Interoperability". This article dives into how multimodal AI platforms and natural language processing (NLP) are reshaping clinical trials. ?? Key insights from the article: - Over 80% of healthcare data is unstructured (clinical notes, imaging reports, etc.) and is often overlooked in traditional recruitment processes. - By leveraging NLP and data models like OMOP CDM, fragmented data can be transformed into standardized, actionable insights. - The impact is profound: improving patient identification, optimizing trial design, and accelerating recruitment timelines. ?? Highlighted outcomes: - In a recent study, these technologies identified 20% more eligible patients, reducing trial delays and significantly lowering costs.?This innovation not only advances clinical trials but also strengthens the focus on personalized medicine and real-world evidence (RWE) generation. ???????? Implications: - These technologies promise to revolutionize how we design and conduct trials, enabling more effective and tailored treatments while aligning with initiatives like the European Health Data Space (EHDS). Congratulations to Rohit, Mats, and Gabriel for this publication! ???? https://lnkd.in/djJdT92y?

?Last week, Applied Clinical Trials Magazine held a roundtable to address industry challenges brought on by underrepresenting racial and ethnic groups in clinical trials. Learn more about these challenges from industry experts such as Sophia McLeod, Sr. Director of Government Relations at ACRO: https://bit.ly/48Nyfmk

The Phase III CLEAR SYNERGY trial found that long-term #colchicine treatment after acute myocardial infarction does not reduce major cardiovascular events compared to placebo, highlighting mixed results from prior studies on its efficacy in #cardiovasculardisease.

?? In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, highlights the #clinicalresearch industry’s need for more regulation around #collectingdata

Cardiac Monitoring Reinvented: AI, Safety, and the Data Impact It's accelerating: advanced ECG technologies and AI are reshaping clinical trials, enhancing both data accuracy and operational efficiency. Don't miss this expert discussion with AliveCor on how these innovations can be seamlessly integrated into your research. Register now: https://ow.ly/uhcW50UaeTg

The answer comes down to context of use—and knowing the motives for "missingness." ??? Scottie Kern, Executive Director, eCOA Consortium at Critical Path Institute (C-Path)